Heron Therapeutics | HRTX - Selling And Administration Expenses


Heron Therapeutics reported $23.74M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
ALKERMES USD 196.64M 67.96M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 91.66M 18.01M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.47M 208K Jun/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
Merck USD 2.89B 219M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.81M 7.93M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Veracyte USD 55.71M 4.87M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026